Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$63.29 USD
-2.96 (-4.47%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $65.18 +1.89 (2.99%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MNPR 63.29 -2.96(-4.47%)
Will MNPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength
Other News for MNPR
MNPR forms Boomer Buy Setup on September 20
Jack-in-the-box Bullish appears for MNPR after 0.59% move
MNPR makes New 52 Week Closing High on September 18
New 52 Week Closing High appears for MNPR after 4.61% move
Raymond James Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)